FDA
-
-
-
-
-
-
-
Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
-
-
-
-
-
-
-
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophreni
-
-
-
-
-
-
-
TEVA secures $500 million funding from Royalty Pharma for vitiligo drug
-
-
-
-
-
-
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
-
-
-
-
-
-
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
-
-
-
-
-
-
-
Teva (TEVA) and Medincell Announce FDA Acceptance of sNDA for UZEDY Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
-
-
-
-
-
-
-
Alvotech (ALVO) and Teva (TEVA) Announce U.S. FDA Approval of Additional Presentation of SELARSDI, Expanding its Label
-
322,946 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

